Erratum: Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study (The Lancet (2018) 391(10127) (1263–1273), (S0140673618304756) (10.1016/S0140-6736(18)30475-6));Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

The Lancet

Volumn 391, Issue 10127, 2018, Pages 1263-1273

  Kappos, Ludwig ^a   Bar Or, Amit ^b,c   Cree, Bruce A C ^d   Fox, Robert J ^e   Giovannoni, Gavin ^f   Gold, Ralf ^g   Vermersch, Patrick ^h,l   Arnold, Douglas L ^c,i   Arnould, Sophie ^j   Scherz, Tatiana ^j   Wolf, Christian ^k   Wallström, Erik ^j   Dahlke, Frank ^j   Achiron, Anat ^l   Achtnichts, Lutz ^l   Agan, Kadriye ^l   Akman Demir, Gulsen ^l   Allen, Alison B ^l   Antel, Jack P ^l   Antiguedad, Alfredo Rodriguez ^l   Apperson, Michelle ^l   Applebee, Angela M ^l   Ayuso, Guillermo Izquierdo ^l   Baba, Masayuki ^l   Bajenaru, Ovidiu ^l   Balasa, Rodica ^l   Balci, Belgin Petek ^l   Barnett, Michael ^l   Bass, Ann ^l   Becker, Veit U ^l   Bejinariu, Mihaela ^l   Bergh, Florian Then ^l   Bergmann, Arnfin ^l   Bernitsas, Evanthia ^l   Berthele, Achim ^l   Bhan, Virender ^l   Bischof, Felix ^l   Bjork, Randall John ^l   Blevins, Gregg ^l   Boehringer, Matthias ^l   Boerner, Thomas ^l   Bonek, Robert ^l   Bowen, James D ^l   Bowling, Allen ^l   Boyko, Alexey N ^l   Boz, Cavit ^l   Bracknies, Vera ^l   Braune, Stefan ^l   Brescia Morra, Vincenzo ^l   Brochet, Bruno ^l   Brola, Waldemar ^l   Brownstone, Paul Kenneth ^l   Brozman, Miroslav ^l   Brunet, Donald ^l   Buraga, Ioan ^l   Burnett, Margaret ^l   Buttmann, Mathias ^l   Butzkueven, Helmut ^l   Cahill, Jonathan ^l   Calkwood, Jonathan C ^l   Camu, William ^l   Cascione, Mark ^l   Castelnovo, Giovani ^l   Centonze, Diego ^l   Cerqueira, Joao ^l   Chan, Andrew ^l   Cimprichova, Andrea ^l   Cohan, Stanley ^l   Comi, Giancarlo ^l   Conway, Jill ^l   Cooper, Joanna A ^l   Corboy, John ^l   Correale, Jorge ^l   Costell, Brian ^l   Cottrell, David A ^l   Coyle, Patricia K ^l   Craner, Matthew ^l   Cui, Liying ^l   Cunha, Luis ^l   Czlonkowska, Anna ^l   da Silva, Ana Martins ^l   de Sa, Joao ^l   de Seze, Jérôme ^l   Debouverie, Marc ^l   Debruyne, Jan ^l   Decoo, Danny ^l   Defer, Gilles ^l   Derfuss, Tobias ^l   Deri, Norma H ^l   Dihenia, Bhupesh ^l   Dioszeghy, Peter ^l   Donath, Vladimir ^l   Dubois, Benedicte ^l   Duddy, Martin ^l   Duquette, Pierre ^l   Edan, Gilles ^l   Efendi, Husnu ^l   Elias, Stanton ^l   Emrich, Peter J ^l   Estruch, Bonaventura Casanova ^l   Evdoshenko, Evgeniy P ^l   Faiss, Juergen ^l   Fedyanin, Alexander S ^l   Feneberg, Wolfgang ^l   Fermont, Jiske ^l   Fernandez, Oscar Fernandez ^l   Ferrer, Francisco Coret ^l   Fink, Katharina ^l   Ford, Helen ^l   Ford, Corey ^l   Francia, Ada ^l   Freedman, Mark ^l   Frishberg, Benjamin ^l   Galgani, Simonetta ^l   Garmany, George P ^l   Gehring, Klaus ^l   Gitt, Jeffrey ^l   Gobbi, Claudio ^l   Goldstick, Lawrence P ^l   Gonzalez, Rafael Arroyo ^l   Grandmaison, Francois ^l   Grigoriadis, Nikolaos ^l   Grigorova, Olga ^l   Grimaldi, Luigi Maria Edoardo ^l   Gross, Jeffrey ^l   Gross Paju, Katrin ^l   Gudesblatt, Mark ^l   Guillaume, Daniel ^l   Haas, Judith ^l   Hancinova, Viera ^l   Hancu, Anca ^l   Hardiman, Orla ^l   Harmjanz, Arndt ^l   Heidenreich, Fedor R ^l   Hengstman, G J D ^l   Herbert, Joseph ^l   Herring, Mark ^l   Hodgkinson, Suzanne ^l   Hoffmann, Olaf M ^l   Hofmann, Werner E ^l   Honeycutt, William D ^l   Hua, Le Hanh ^l   Huang, Dehui ^l   Huang, Yining ^l   Huang, DeRen ^l   Hupperts, Raymond ^l   Imre, Piroska ^l   Jacobs, Alan Keith ^l   Jakab, Gabor ^l   Jasinska, Elzbieta ^l   Kaida, Kenichi ^l   Kalnina, Jolanta ^l   Kaprelyan, Ara ^l   Karelis, Guntis ^l   Karussis, Dimitrios ^l   Katz, Amos ^l   Khabirov, Farit A ^l   Khatri, Bhupendra ^l   Kimura, Takashi ^l   Kister, Ilya ^l   Kizlaitiene, Rasa ^l   Klimova, Eleonora ^l   Koehler, Juergen ^l   Komatineni, Aparna ^l   Kornhuber, Anselm ^l   Kovacs, Krisztina ^l   Koves, Agnes ^l   Kozubski, Wojciech ^l   Krastev, Georgi ^l   Krupp, Lauren B ^l   Kurca, Egon ^l   Lassek, Christoph ^l   Laureys, Guy ^l   Lee, Liesly ^l   Lensch, Eckart ^l   Leutmezer, Fritz ^l   Li, Hongzeng ^l   Linker, Ralf A ^l   Linnebank, Michael ^l   Liskova, Petra ^l   Llanera, Cristina ^l   Lu, Jiahong ^l   Lutterotti, Andreas ^l   Lycke, Jan ^l   Macdonell, Richard ^l   Maciejowski, Maciej ^l   Maeurer, Mathias ^l   Magzhanov, Rim V ^l   Maida, Eva Maria ^l   Malciene, Lina ^l   Mao Draayer, Yang ^l   Marfia, Girolama Alessandra ^l   Markowitz, Clyde ^l   Mastorodimos, Vasileios ^l   Matyas, Klotild ^l   Meca Lallana, Jose ^l   Merino, Juan Antonio Garcia ^l   Mihetiu, Ioan Gheorghe ^l   Milanov, Ivan ^l   Miller, Aaron E ^l   Millers, Andrejs ^l   Mirabella, Massimiliano ^l   Mizuno, Masanori ^l   Montalban, Xavier ^l   Montoya, Lilina ^l   Mori, Masahiro ^l   Mueller, Stefanie ^l   Nakahara, Jin ^l   Nakatsuji, Yuji ^l   Newsome, Scott ^l   Nicholas, Richard ^l   Nielsen, A Scott ^l   Nikfekr, Esmaeil ^l   Nocentini, Ugo ^l   Nohara, Chiyoko ^l   Nomura, Kyoichi ^l   Odinak, Miroslav M ^l   Olsson, Tomas ^l   van Oosten, B W ^l   Oreja Guevara, Celia ^l   Oschmann, Patrick ^l   Overell, James ^l   Pachner, Andrew ^l   Panczel, Gyula ^l   Pandolfo, Massimo ^l   Papeix, Caroline ^l   Patrucco, Liliana ^l   Pelletier, Jean ^l   Piedrabuena, Raul ^l   Pless, Misha ^l   Polzer, Udo ^l   Pozsegovits, Krisztian ^l   Rastenyte, Daiva ^l   Rauer, Sebastian ^l   Reifschneider, Gerd ^l   Rey, Roberto ^l   Rizvi, Syed A ^l   Robertson, Derrick ^l   Rodriguez, Jose Martinez ^l   Rog, David ^l   Roshanisefat, Homayoun ^l   Rowe, Vernon ^l   Rozsa, Csilla ^l   Rubin, Susan ^l   Rusek, Stanislaw ^l   Saccà, Francesco ^l   Saida, Takahiko ^l   Salgado, Antonio Vasco ^l   Sanchez, Victoria Eugenia Fernandez ^l   Sanders, Kalina ^l   Satori, Maria ^l   Sazonov, Denis V ^l   Scarpini, Elio Angelo ^l   Schlegel, Eugen ^l   Schluep, Myriam ^l   Schmidt, Stephan ^l   Scholz, Erich ^l   Schrijver, H M ^l   Schwab, Matthias ^l   Schwartz, Raymond ^l   Scott, James ^l   Selmaj, Krzysztof ^l   Shafer, Stuart ^l   Sharrack, Basil ^l   Shchukin, Ivan A ^l   Shimizu, Yuko ^l   Shotekov, Penko ^l   Siever, Arno ^l   Sigel, Karl Otto ^l   Silliman, Scott ^l   Simo, Magdolna ^l   Simu, Mihaela ^l   Sinay, Vladimiro ^l   Siquier, Antonio Escartin ^l   Siva, Aksel ^l   Skoda, Ondrej ^l   Solomon, Andrew ^l   Stangel, Martin ^l   Stefoski, Dusan ^l   Steingo, Brian ^l   Stolyarov, Igor D ^l   Stourac, Pavel ^l   Strassburger Krogias, Katrin ^l   Strauss, Erik ^l   Stuve, Olaf ^l   Tarnev, Ivaylo ^l   Tavernarakis, Antonios ^l   Tello, Cristina Ramo ^l   Terzi, Murat ^l   Ticha, Veronika ^l   Ticmeanu, Marina ^l   Tiel Wilck, Klaus ^l   Toomsoo, Toomas ^l   Tubridy, Niall ^l   Tullman, Mark J ^l   Tumani, Hayrettin ^l   Turcani, Peter ^l   Turner, Ben ^l   Uccelli, Antonio ^l   Urtaza, Francisco Javier Olascoaga ^l   Vachova, Marta ^l   Valikovics, Attila ^l   Walter, Silke ^l   Van Wijmeersch, Bart ^l   Vanopdenbosch, Ludo ^l   Weber, Joerg R ^l   Weiss, Sara ^l   Weissert, Robert ^l   West, Timothy ^l   Wiendl, Heinz ^l   Wiertlewski, Sandrine ^l   Wildemann, Brigitte ^l   Willekens, Barbara ^l   Visser, L H ^l   Vorobeychik, Galina ^l   Xu, Xianhao ^l   Yamamura, Takashi ^l   Yang, Yi N ^l   Yelamos, Sergio Martinez ^l   Yeung, Michael ^l   Zacharias, Alan ^l   Zelkowitz, Marvin ^l   Zettl, Uwe ^l   Zhang, Meini ^l   Zhou, Hongyu ^l   Zieman, Ulf ^l   Ziemssen, Tjalf ^l   more..

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g ST JOSEF HOSPITAL   (Germany)

^h UNIV LILLE   (France)

ⁱ NEURORX RESEARCH   (Canada)

^j NOVARTIS PHARMA AG   (Switzerland)

^k Lycalis Bruxelles   (Belgium)

^l NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PLACEBO; SIPONIMOD; 1-(4-(1-((E)-4-CYCLOHEXYL-3-TRIFLUOROMETHYLBENZYLOXYIMINO)-ETHYL)-2-ETHYLBENZYL)-AZETIDINE-3-CARBOXYLIC ACID; AZETIDINE DERIVATIVE; BENZYL DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASAL CELL CARCINOMA; BRADYCARDIA; CAUSE OF DEATH; CONCUSSION; CONTROLLED STUDY; CONVULSION; DEPRESSION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FALLING; FEMALE; GAIT DISORDER; HEADACHE; HERPES ZOSTER; HERPES ZOSTER MENINGITIS; HUMAN; HYPERTENSION; INFECTION; INFESTATION; LUNG METASTASIS; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; OPEN STUDY; PARAPLEGIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RHINOPHARYNGITIS; RISK REDUCTION; SIDE EFFECT; SINUS BRADYCARDIA; SUICIDE ATTEMPT; THROMBOEMBOLISM; URINARY TRACT INFECTION; VIRUS MENINGITIS; YOUNG ADULT; ADOLESCENT; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE EXACERBATION; DOSE RESPONSE; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AZETIDINES; BENZYL COMPOUNDS; COHORT STUDIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85044304126     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)32834-4     Document Type: Erratum

References (27)

1. Tremlett, H, Yinshan, Z, Devonshire, V, Natural history of secondary-progressive multiple sclerosis. Mult Scler 14 (2008), 314–324.
2. Scalfari, A, Neuhaus, A, Daumer, M, Muraro, PA, Ebers, GC, Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry 85 (2014), 67–75.
3. Lublin, FD, Reingold, SC, Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46 (1996), 907–911.
4. Lublin, FD, Reingold, SC, Cohen, JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83 (2014), 278–286.
5. Shirani, A, Okuda, DT, Stuve, O, Therapeutic advances and future prospects in progressive forms of multiple sclerosis. Neurotherapeutics 13 (2016), 58–69.
6. Steiner, D, Arnold, D, Freedman, MS, et al. Natalizumab versus placebo in patients with secondary progressive multiple sclerosis (SPMS): results from ASCEND, a multicenter, double-blind, placebo-controlled, randomized phase 3 clinical trial. Neurology, 86(16 supplement), 2016, E22.
7. Panitch, H, Miller, A, Paty, D, Weinshenker, B, Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63 (2004), 1788–1795.
8. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 352 (1998), 1491–1497.
9. Kappos, L, Weinshenker, B, Pozzilli, C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 63 (2004), 1779–1787.
10. Gergely, P, Nuesslein-Hildesheim, B, Guerini, D, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol 167 (2012), 1035–1047.
11. Brinkmann, V, FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol 158 (2009), 1173–1182.
12. Aslanis, V, Faller, T, Van de Kerkhof, E, Schubart, A, Wallström, E, Beyerbach, A, Siponimod (BAF312) (and/or its metabolites) penetrates into the CNS and distributes to white matter areas. Mult Scler 18:4 suppl (2012), 279–508.
13. Gentile, A, Musella, A, Bullitta, S, et al. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. J Neuroinflammation, 13, 2016, 207.
14. Jackson, SJ, Giovannoni, G, Baker, D, Fingolimod modulates microglial activation to augment markers of remyelination. J Neuroinflammation, 8, 2011, 76.
15. Selmaj, K, Li, DK, Hartung, HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 12 (2013), 756–767.
16. Rovaris, M, Confavreux, C, Furlan, R, Kappos, L, Comi, G, Filippi, M, Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 5 (2006), 343–354.
17. Kurtzke, JF, Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983), 1444–1452.
18. Polman, CH, Reingold, SC, Banwell, B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69 (2011), 292–302.
19. World Medical Association. WMA Declaration of Helsinki—ethical principles for medical research involving human subjects. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ (accessed Oct 25, 2016).
20. D'Souza, M, Yaldizli, O, John, R, et al. Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: a proof of concept study. Mult Scler 23 (2017), 597–603.
21. Roxburgh, RH, Seaman, SR, Masterman, T, et al. Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology 64 (2005), 1144–1151.
22. O'Brien, PC, Fleming, TR, A multiple testing procedure for clinical trials. Biometrics 35 (1979), 549–556.
23. Montalban, X, Hauser, SL, Kappos, L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376 (2017), 209–220.
24. Bennett, SE, Bromley, LE, Fisher, NM, Tomita, MR, Niewczyk, P, Validity and reliability of four clinical gait measures in patients with multiple sclerosis. Int J MS Care 19 (2017), 247–252.
25. Tanigawa, M, Stein, J, Park, J, Kosa, P, Cortese, I, Bielekova, B, Finger and foot tapping as alternative outcomes of upper and lower extremity function in multiple sclerosis. Mult Scler J Exp Transl Clin, 3, 2017 2055217316688930.
26. Ebers, GC, Heigenhauser, L, Daumer, M, Lederer, C, Noseworthy, JH, Disability as an outcome in MS clinical trials. Neurology 71 (2008), 624–631.
27. Kappos, L, Radue, EW, O'Connor, P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362 (2010), 387–401.